Study tracking pregnancy outcomes after tildrakizumab use
Part of Women’s health & pregnancy clinical trials.
This study follows pregnant people who took tildrakizumab to understand pregnancy outcomes and safety. It also compares them with pregnant people with the same underlying disease who did not take tildrakizumab during this pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently pregnant
- For the tildrakizumab group: you took tildrakizumab during this pregnancy for an approved reason
- For the comparison group: you have the same approved disease, but did NOT take tildrakizumab during this pregnancy
- You must agree to interview questions during pregnancy and after delivery
- You must agree to share your medical records for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at women who used a topical eczema cream called ruxolitinib (Opzelura) or steroid creams during pregnancy. The goal is to compare pregnancy outcomes and baby health up to one year after birth.
This study looks at how monoclonal antibody treatments given during pregnancy affect a baby's immune system development. It compares babies whose mothers received these treatments throughout pregnancy, only in early pregnancy, or not at all.
This study follows pregnant women and their babies to see how well HIV prevention medicines work during pregnancy. It aims to help keep both mother and baby healthy.
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
This study looks at how safe the medicine deucravacitinib (used for psoriasis) is during pregnancy. It compares pregnant women who took deucravacitinib to those who did not, to see if there are any effects on the baby.
Hear when a new Pregnancy Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.